

Express Mail Label No.: EV399525755US
Date of Deposit: April 6, 2004

Please type a plus sign (+) in this box

Page 1 of 3

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Application Number 10/665,079

Filing Date 09/16/03

First Named Inventor Bacopoulos

Group Art Unit 1614

Examiner Name Not Yet Assigned

Attorney Docket Number 24852-501 CIP5

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A1*	5,055,608	10/08/91	Marks et al.	560	169	06/30/89
	A2*	5,175,191	12/29/92	Marks et al.	514	575	05/14/90
	A3*	5,369,108	11/29/94	Breslow et al.	514	266	10/04/91
	A4*	5,608,108	03/04/97	Marks et al.	562	621	04/17/95
	A5*	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94
	A6*	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95
	A7*	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94
	A8*	6,087,367	06/11/00	Breslow et al.	514	266	05/18/99
	A9*	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
1	B1*	WO 98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X
1	B2*	WO 00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X
1	B3*	WO 00/71703	Methylgene, Inc.	November 30, 2000	X
1	B4*	WO 01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X
1	B5*	WO 01/38322	Methylgene, Inc.	May 31, 2001	X
1	B6*	WO 01/70675	Methylgene, Inc.	September 27, 2001	X
1	B7*	WO 02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X
1	B8*	WO 02/30879	Prolifix Limited	April 18, 2002	X
1	B9*	WO 02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
1	C1*	Andrews et al. (2000). <i>Intl. J. Parasitol.</i> 30: 761-768.
1	C2*	Archer et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 6791-6796.
1	C3*	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." <i>American Society of Hematology, 44th Meeting of the American Society of Hematology, Abstract 4611.</i>
1	C4*	Butler et al. (2000). <i>Cancer Res.</i> 60: 5165-5170.
1	C5*	Butler et al. (2001). <i>Clinical Cancer Res.</i> 7: 962-970.
1	C6*	Butler et al. (2002). <i>Proc. Natl. Acad. Sci. USA</i> 99: 11700-11705.
1	C7*	Coffey et al. (2000). <i>Medical and Pediatric Oncology</i> 35: 577-581.

I did not receive

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
1	C8*	Coffey et al. (2001). <i>Cancer Res.</i> <u>61</u> : 3591-3594.
1	C9*	Cohen et al. (1999). <i>Anticancer Res.</i> <u>19</u> : 4999-5006.
1	C10*	Cohen et al. (2002). <i>Anticancer Res.</i> <u>22</u> : 1497-1504.
1	C11*	Curtin (2002). <i>Exp. Opin. Ther. Patents</i> <u>12</u> : 1375-1384.
1	C12*	Dressel (2000). <i>Anticancer Res.</i> <u>20</u> : 1017-1022.
1	C13*	Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology Abstract No. 4602.
1	C14*	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract No. 3195.
1	C15*	Finnin et al. (1999). <i>Nature</i> <u>401</u> : 188-193.
1	C16*	Furamai et al. (2001). <i>Proc. Natl. Sci. USA</i> <u>98</u> : 87-92.
1	C17*	Grunstein (1997). <i>Nature</i> <u>389</u> : 349-352.
1	C18*	He et al. (2001). <i>J. Clin. Investigation</i> <u>108</u> : 1321-1330.
1	C19*	Hockly et al. (2003). <i>Proc. Natl. Acad. Sci. USA</i> <u>100</u> : 2041-2046.
1	C20*	Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." <i>American Society of Clinical Oncology</i> , Abstract No. 344.
1	C21*	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." <i>American Society of Clinical Oncology</i> , 38 th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831.
1	C22*	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." <i>European J. Cancer</i> <u>38</u> (Suppl. 7): 88, Abstract No. 286.
1	C23*	Kim et al. (1999). <i>Oncogene</i> <u>18</u> : 2461-2470.
1	C24*	Kohge et al. (1998). <i>Biochem. Pharmacol.</i> <u>56</u> : 1359-1364.
1	C25*	Komatsu et al. (2001). <i>Cancer Res.</i> <u>61</u> : 4459-4466.
1	C26*	Kouraklis and Theocharis (2002). <i>Curr. Med. Chem. Anti-Cancer Agents</i> <u>2</u> : 477-484.
1	C27*	Lee et al. (2001). <i>Cancer Res.</i> <u>61</u> : 931-934.
1	C28*	Lin et al. (1998). <i>Nature</i> <u>391</u> : 811-814.
1	C29*	Mai et al. (2001). <i>OPPI Briefs</i> <u>33</u> : 391-394
1	C30*	Marks et al. (2000). <i>J. of the Natl. Cancer Institute</i> <u>92</u> : 1210-1215.
1	C31*	Marks et al. (2001). <i>Clinical Cancer Res.</i> <u>7</u> : 759-760.
1	C32*	Marks et al. (2001). <i>Curr. Opin. In Oncology</i> <u>13</u> : 477-483.
1	C33*	Marks et al. (2001). <i>Nature Reviews</i> <u>1</u> : 194-202.
1	C34*	Miller et al. (2003). <i>J Med Chem.</i> <u>46</u> : 5097-5116.
1	C35*	Munster et al. (2001). <i>Cancer Res.</i> <u>61</u> : 8492-8497.
1	C36*	O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." <i>American Society of Clinical Oncology</i> , December 6-10, 2002, Abstract No. 4742.
1	C37*	Qui et al. (2000). <i>Mol. Biol. Cell</i> <u>11</u> : 2069-2083.
1	C38*	Richon et al. (1996). <i>Proc. Natl. Acad. Sci. USA</i> <u>93</u> : 5705-5708.
1	C39*	Richon et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> <u>95</u> : 3003-3007.
1	C40*	Richon et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 10014-10019.
1	C41*	Richon and O'Brien (2002). <i>Clinical Cancer Res.</i> <u>8</u> : 662-664.
1	C42*	Saito et al. (1999). <i>Proc. Natl. Acad. Sci. USA</i> <u>96</u> : 4592-4597.
1	C43*	Sgouros et al. (2002). "Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and

, did not receive

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		Radiation in Human Prostate Tumor Spheroids.* <i>American Society of Clinical Oncology, Abstract No. 105.</i>
	C44*	Stowell et al. (1995). <i>J. Med. Chem.</i> <u>38</u> : 1411-1413.
	C45*	Su et al. (2000). <i>Cancer Res.</i> <u>60</u> : 3137-3142.
	C46*	Suzuki et al. (1999). <i>J. Med. Chem.</i> <u>42</u> : 3001-3003.
	C47*	Van Lint et al. (1996). <i>Gene Expression</i> <u>5</u> : 245-253.
	C48*	Vrana et al. (1999). <i>Oncogene</i> <u>18</u> : 7016-7025.
	C49*	Webb et al. (1999). <i>J. Biol. Chem.</i> <u>274</u> : 14280-14287.
	C50*	Yoshida et al. (1990). <i>J. Biol. Chem.</i> <u>265</u> : 17174-17179.
	C51*	Yoshida et al. (1995). <i>BioEssays</i> <u>17</u> : 423-430.
	C52*	Zhou et al. (1999). <i>Gene</i> <u>233</u> : 13-19.
	C53*	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 1056-1061.
	C54*	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 14329-14333.
	C55*	Zhou et al. (2001). <i>Proc. Natl. Acad. Sci. USA</i> <u>98</u> : 10572-10577.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/379,149, filed March 4, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1) did not receive

Express Mail Label No.: EV334317572US
Date of Deposit: February 26, 2004

Page 1 of 3

Please type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

O I P E J C Y
FEB 26 2004
PATENT & TRADEMARK OFFICE

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number 10/379,149
		Filing Date March 4, 2003
		First Named Inventor Victoria M. Richon and Judy H. Chiao
		Group Art Unit 1614
		Examiner Name Not Yet Assigned
		Attorney Docket Number 24852-501

U.S. PATENT DOCUMENTS						
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class
	A1	5,055,608	10/08/91	Marks et al.	560	169
	A2	5,175,191	12/29/92	Marks et al.	514	575
	A3	5,369,108	11/29/94	Breslow et al.	514	266
	A4	5,608,108	03/04/97	Marks et al.	562	621
	A5	5,700,811	12/23/97	Breslow et al.	514	314
	A6	5,773,474	06/30/98	Breslow et al.	514	616
	A7	5,932,616	08/13/99	Breslow et al.	514	532
	A8	6,087,367	06/11/00	Breslow et al.	514	266
	A9	6,511,990	01/28/03	Breslow et al.	514	314


FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X
	B2	WO 00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X
	B3	WO 00/71703	Methylgene, Inc.	November 30, 2000	X
	B4	WO 01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X
	B5	WO 01/38322	Methylgene, Inc.	May 31, 2001	X
	B6	WO 01/70675	Methylgene, Inc.	September 27, 2001	X
	B7	WO 02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X
	B8	WO 02/30879	Prolifix Limited	April 18, 2002	X
	B9	WO 02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Andrews et al. (2000). <i>Intl. J. Parasitol.</i> 30: 761-768.
	C2	Archer et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 6791-6796.
	C3	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." <i>American Society of Hematology, 44th Meeting of the American Society of Hematology, Abstract 4611.</i>
	C4	Butler et al. (2000). <i>Cancer Res.</i> 60: 5165-5170.
	C5	Butler et al. (2001). <i>Clinical Cancer Res.</i> 7: 962-970.
	C6	Butler et al. (2002). <i>Proc. Natl. Acad. Sci. USA</i> 99: 11700-11705.
	C7	Coffey et al. (2000). <i>Medical and Pediatric Oncology</i> 35: 577-581.

FEB 26 2004

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C8	Coffey et al. (2001). <i>Cancer Res.</i> <u>61</u> : 3591-3594.
	C9	Cohen et al. (1999). <i>Anticancer Res.</i> <u>19</u> : 4999-5006.
	C10	Cohen et al. (2002). <i>Anticancer Res.</i> <u>22</u> : 1497-1504.
	C11	Curtin (2002). <i>Exp. Opin. Ther. Patents</i> <u>12</u> : 1375-1384.
	C12	Dressel (2000). <i>Anticancer Res.</i> <u>20</u> : 1017-1022.
	C13	Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology Abstract No. 4602.
	C14	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract No. 3195.
	C15	Finnin et al. (1999). <i>Nature</i> <u>401</u> : 188-193.
	C16	Furamai et al. (2001). <i>Proc. Natl. Sci. USA</i> <u>98</u> : 87-92.
	C17	Grunstein (1997). <i>Nature</i> <u>389</u> : 349-352.
	C18	He et al. (2001). <i>J. Clin. Investigation</i> <u>108</u> : 1321-1330.
	C19	Hockly et al. (2003). <i>Proc. Natl. Acad. Sci. USA</i> <u>100</u> : 2041-2046.
	C20	Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." <i>American Society of Clinical Oncology</i> , Abstract No. 344.
	C21	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." <i>American Society of Clinical Oncology</i> , 38 th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831.
	C22	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." <i>European J. Cancer</i> <u>38</u> (Suppl. 7): 88, Abstract No. 286.
	C23	Kim et al. (1999). <i>Oncogene</i> <u>18</u> : 2461-2470.
	C24	Kohge et al. (1998). <i>Biochem. Pharmacol.</i> <u>56</u> : 1359-1364.
	C25	Komatsu et al. (2001). <i>Cancer Res.</i> <u>61</u> : 4459-4466.
	C26	Kouraklis and Theocharis (2002). <i>Curr. Med. Chem.-Anti-Cancer Agents</i> <u>2</u> : 477-484.
	C27	Lee et al. (2001). <i>Cancer Res.</i> <u>61</u> : 931-934.
	C28	Lin et al. (1998). <i>Nature</i> <u>391</u> : 811-814.
	C29	Mai et al. (2001). <i>OPPI Briefs</i> <u>33</u> : 391-394
	C30	Marks et al. (2000). <i>J. of the Natl. Cancer Institute</i> <u>92</u> : 1210-1215.
	C31	Marks et al. (2001). <i>Clinical Cancer Res.</i> <u>7</u> : 759-760.
	C32	Marks et al. (2001). <i>Curr. Opin. In Oncology</i> <u>13</u> : 477-483.
	C33	Marks et al. (2001). <i>Nature Reviews</i> <u>1</u> : 194-202.
	C34	Miller et al. (2003). <i>J Med Chem.</i> <u>46</u> : 5097-5116.
	C35	Munster et al. (2001). <i>Cancer Res.</i> <u>61</u> : 8492-8497.
	C36	O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." <i>American Society of Clinical Oncology</i> , December 6-10, 2002, Abstract No. 4742.
	C37	Qui et al. (2000). <i>Mol. Biol. Cell</i> <u>11</u> : 2069-2083.
	C38	Richon et al. (1996). <i>Proc. Natl. Acad. Sci. USA</i> <u>93</u> : 5705-5708.
	C39	Richon et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> <u>95</u> : 3003-3007.
	C40	Richon et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 10014-10019.
	C41	Richon and O'Brien (2002). <i>Clinical Cancer Res.</i> <u>8</u> : 662-664.
	C42	Saito et al. (1999). <i>Proc. Natl. Acad. Sci. USA</i> <u>96</u> : 4592-4597.
	C43	Sgouros et al. (2002). "Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		Radiation in Human Prostate Tumor Spheroids." <i>American Society of Clinical Oncology</i> , Abstract No. 105.
	C44	Stowell et al. (1995). <i>J. Med. Chem.</i> <u>38</u> : 1411-1413.
	C45	Su et al. (2000). <i>Cancer Res.</i> <u>60</u> : 3137-3142.
	C46	Suzuki et al. (1999). <i>J. Med. Chem.</i> <u>42</u> : 3001-3003.
	C47	Van Lint et al. (1996). <i>Gene Expression</i> <u>5</u> : 245-253.
	C48	Vrana et al. (1999). <i>Oncogene</i> <u>18</u> : 7016-7025.
	C49	Webb et al. (1999). <i>J. Biol. Chem.</i> <u>274</u> : 14280-14287.
	C50	Yoshida et al. (1990). <i>J. Biol. Chem.</i> <u>265</u> : 17174-17179.
	C51	Yoshida et al. (1995). <i>BioEssays</i> <u>17</u> : 423-430.
	C52	Zhou et al. (1999). <i>Gene</i> <u>233</u> : 13-19.
	C53	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 1056-1061.
	C54	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> <u>97</u> : 14329-14333.
	C55	Zhou et al. (2001). <i>Proc. Natl. Acad. Sci. USA</i> <u>98</u> : 10572-10577.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.